191 related articles for article (PubMed ID: 26977031)
21. [Cisplatin and cytosine arabinoside (ARA-C) for the therapy of primary and secondary pleural neoplasms].
Aitini E; Cavazzini G; Cantore M; Rabbi C; Smerieri F
G Ital Oncol; 1990; 10(3):85-8. PubMed ID: 2286397
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of the therapeutic effects of pleural perfusion of NDP and cDDP in NSCLC patients with malignant pleural effusion].
Cong YY; Liu MY; Cai L
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):467-9. PubMed ID: 20819493
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
Sakaguchi H; Ishida H; Nitanda H; Yamazaki N; Kaneko K; Kobayashi K
Lung Cancer; 2017 Feb; 104():70-74. PubMed ID: 28213004
[TBL] [Abstract][Full Text] [Related]
25. Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil.
Jia W; Zhu Z; Zhang T; Fan G; Fan P; Liu Y; Duan Q
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1585-90. PubMed ID: 23589316
[TBL] [Abstract][Full Text] [Related]
26. [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Hada M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):613-7. PubMed ID: 15114711
[TBL] [Abstract][Full Text] [Related]
27. Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study.
Aitini E; Cavazzini G; Pasquini E; Rabbi C; Colombo F; Cantore M; Fattori PP; Pari F; Bertuzzi A; Smerieri F
Acta Oncol; 1994; 33(2):191-4. PubMed ID: 8204275
[TBL] [Abstract][Full Text] [Related]
28. Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more.
Chen D; Song X; Zhang Y; Kong L; Wang H; Yu J
Future Oncol; 2018 Sep; 14(21):2131-2138. PubMed ID: 29546764
[TBL] [Abstract][Full Text] [Related]
29. Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer.
Song X; Chen D; Guo J; Kong L; Wang H; Wang Z
Onco Targets Ther; 2018; 11():8421-8426. PubMed ID: 30568464
[TBL] [Abstract][Full Text] [Related]
30. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial.
Seto T; Ushijima S; Yamamoto H; Ito K; Araki J; Inoue Y; Semba H; Ichinose Y;
Br J Cancer; 2006 Sep; 95(6):717-21. PubMed ID: 16940982
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of the prognosis of 111 patients with gastric cancer or adenocarcinoma of the esophagogastric junction combined with pleural or abdominal effusion].
Liu Y; Du CX; Zhang HG
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):693-7. PubMed ID: 24332058
[TBL] [Abstract][Full Text] [Related]
32. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion.
Matsuzaki Y; Shibata K; Yoshioka M; Inoue M; Sekiya R; Onitsuka T; Iwamoto I; Koga Y
Ann Thorac Surg; 1995 Jan; 59(1):127-31. PubMed ID: 7818311
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis.
Hu Y; Zhou Z; Luo M
Medicine (Baltimore); 2022 Dec; 101(52):e32207. PubMed ID: 36595983
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of intraperitoneal or intrapleural administration of triamcinolone acetonide for the control of malignant ascites and pleural effusion (Kansai Clinical Oncology Group-G1102 study).
Ito K; Tsubamoto H; Inoue K; Miyoshi Y; Ito Y; Hori K
J Cancer Res Ther; 2017; 13(3):446-450. PubMed ID: 28862207
[TBL] [Abstract][Full Text] [Related]
35. Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion.
Muraoka M; Oka T; Akamine S; Tagawa T; Morinaga M; Inoue M; Yamayoshi T; Hashizume S; Matsumoto K; Hayashi T; Nagayasu T
J Surg Oncol; 2006 Mar; 93(4):323-9. PubMed ID: 16496367
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites.
Zhan Z; Wang X; Yu J; Zheng J; Zeng Y; Sun M; Peng L; Guo Z; Chen B
Future Oncol; 2022 Mar; 18(10):1259-1271. PubMed ID: 35114805
[TBL] [Abstract][Full Text] [Related]
37. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary.
Lind SE; Cashavelly B; Fuller AF
Surg Gynecol Obstet; 1988 Jun; 166(6):519-22. PubMed ID: 3375962
[TBL] [Abstract][Full Text] [Related]
38. [Negative pleural cytology after intrapleural perfusion hyperthermo-chemotherapy for malignant pleural effusion].
Yagi T; Ueda K; Kaneda Y; Sakano H; Tanaka T; Matsuoka T; Sudo M; Hayashi M; Hamano K
Kyobu Geka; 2004 Feb; 57(2):107-10. PubMed ID: 14978902
[TBL] [Abstract][Full Text] [Related]
39. [A case of remission induced in diffuse pleural malignant mesothelioma by the treatment with cisplatin and doxorubicin].
Niki Y; Nakayama S; Soga T; Baba M; Nishimura A; Kato M; Kanamaru M
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3635-8. PubMed ID: 2817912
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion.
Shoji T; Tanaka F; Yanagihara K; Inui K; Wada H
Chest; 2002 Mar; 121(3):821-4. PubMed ID: 11888966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
